Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Zoe Coughlin"'
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Autor:
Dominik Maurer, Borje S. Andersson, Jens Fritsche, Arun Satelli, Sabrina Kuttruff-Coqui, Kerstin Guenther, Carsten Reinhardt, Steffen Walter, Mamta Kalra, Ali Mohamed, Apostolia Maria Tsimberidou, Rita Ort, Kerry Sieger, Norbert Hilf, Amir Alpert, Anna Nowak, Becky Norris, Toni Weinschenk, David Vining, Oliver Schoor, Fabian Richter, Patrick Hwu, Zoe Coughlin, Cassian Yee, Regina Mendrzyk, Harpreet Singh, Claudia Wagner
Publikováno v:
Regular and young investigator award abstracts.
Background ACTolog (IMA101) is a personalized multi-target adoptive cell therapy (ACT) approach in which autologous T-cell products are redirected against multiple novel defined peptide-HLA (pHLA) cancer targets identified by the target discovery pla